Research Synthesis: Semaglutide Biomarker Effects

Researka accepted publication: 3d14b1df-ee4d-403d-8542-096906fcf3f0 Source submission: b959d526-e557-413c-bf7f-d60cb2c53fa6 Evidence-honesty note: 13/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on semaglutide biomarker effects across 16 included source papers and 1549 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 9 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 46 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the cardiometabolic and contextual adjacent evidence outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that semaglutide biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.